# TB-500 FAQ: Side Effects, Safety Signals, BPC-157, and the Research Record

> TB-500 FAQ, cited: side effects and the tumor/angiogenesis signal, the difference between TB-500 and BPC-157, long-term safety, and what the literature actually establishes.

Direct answers about safety signals, comparisons, and evidence — each cited where it makes a quantitative claim.

## Safety signals first

The TB-500 questions readers ask most are safety questions, so this FAQ leads with them. The honest summary up front, including on TB-500 side effects: there is no human side-effect profile for the Ac-LKKTETQ fragment, the closest human safety data come from intravenous full-length thymosin beta-4 [6], and the principal open concern is the tumor and angiogenesis signal. Each answer below states what is known and marks what is not.

---

A chromatic-split scope reading of the TB-500 record — the Ac-LKKTETQ fragment held on one channel and full-length thymosin beta-4 on the other so the two are never mistaken for one trace, the FDA 503A standing read before anything else, with no clinic behind the scope and nothing here dispensed or sold.